‘Game-changer’ drug will not be available on NHS
The Institute of Cancer Research (ICR) has expressed disappointment that the prostate cancer drug abiraterone will not be made available to men with advanced prostate cancer as a first-line treatment on the NHS.
Cancer Nursing Practice.
17, 4, 7-7.
doi: 10.7748/cnp.17.4.7.s4
Want to read more?
Already have access? Log in
or
3-month trial offer for £5.25/month
Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
- Unlimited access to all 10 RCNi Journals
- RCNi Learning featuring over 175 modules to easily earn CPD time
- NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
- Personalised newsletters tailored to your interests
- A customisable dashboard with over 200 topics
Subscribe
Alternatively, you can purchase access to this article for the next seven days.
Buy now
Are you a student? Our student subscription has content especially for you.
Find out more
